Skip to main content

Table 3 Percentage of inhibition of Aβ42 aggregation by Cur or SLCP in comparison to untreated group, *p < 0.05, **p < 0.01, relative to untreated Aβ42

From: RETRACTED ARTICLE: Preservation of dendritic spine morphology and postsynaptic signaling markers after treatment with solid lipid curcumin particles in the 5xFAD mouse model of Alzheimer’s amyloidosis

 

6-E10 antibodies

OC antibodies

A11 antibody

Duration

24 h

48 h

24 h

48 h

8 h

Treatment Groups

Aβ42+

Cur

Aβ42+

SLCP

Aβ42+

Cur

Aβ42+

SLCP

Aβ42+

Cur

Aβ42+

SLCP

Aβ42+

Cur

Aβ42+

SLCP

Aβ42+

Cur

Aβ42+

SLCP

1 μM

64.54

48.34*

26.25

51.68**

16.99

41.04**

18.95

37.11*

24.20

43.75*

100 nM

71.99

48.44**

31.21

58.69**

21.64

30.59

60.81

36.45*

7.63

48.37**

10 nM

63.96

59.76

18.38

65.70**

27.54

35.15

105.15

33.29*

17.59

53.68**

1 nM

65.05

55.82*

37.34

65.00**

23.07

38.70*

− 73.09

56.82**

22.37

46.74*